Trial Profile
Randomized phase II trial of combined chemoradiation [gemcitabine + radiotherapy] with epidermal growth factor receptor (EGFR) antagonist cetuximab versus combined chemoradiation with EGFR antagonist cetuximab and sequential cetuximab for patients with locally advanced pancreatic adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Nov 2019
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PARC
- 13 Dec 2005 New trial record.